JAK Inhibitors Video Perspectives

In this video series, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed:

• How JAK inhibitors “totally transformed the landscape of treatment for patients;”
• The potential of this treatment in non-rheumatologic diseases, like hematologic malignancies, solid tumors and COVID-19;
• The FDA warning on risks associated with JAK inhibitor use;
• Her interpretation of the real-world STAR-RA data presented at ACR 2021 – “you have to balance controlling inflammation versus possible risks or side effects of the drugs;”
• Enforcing lifestyle changes that can mitigate cardiovascular risks in RA patients, like smoking cessation, diabetes control, taking blood pressure medicine and exercising;
• Triple DMARD therapy and other options for patients who don’t respond to JAK inhibitors; and
• JAK inhibitors in the pipeline and her excitement for the second-generation JAK inhibitors.